ClinicalTrials.gg
Active, not recruitingNCT05140369CLL registryUpdated Sep 3, 2026

CLL Therapy Approaches in Russia

An observational study in Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 34 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.

Planned enrollment
Largest of 12
6,000 · median 136
Started
2021
with 5 others
Observational
12 of 42
3 open now
Primary completion
2027-03
later than 11 of 20 live
Registered
31st of 42
by date

Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one has the largest planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2021, is one of 12 observational ones, reaches primary completion later than 11 of the 20 other live ones, and was the 31st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

This is going to be a non-interventional study (NIS). Assessment of variables will be carried out using data on patient's treatment in real-life clinical setting. Patients should be enrolled into study after evaluation of eligibility criteria by the investigator. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice.

Evaluation of efficacy and safety of any approaches used for CLL/SLL treatment is not the primary objective of this study, though there is no treatment of interest. Study procedures will comply with all the local regulatory requirements regarding AE reporting (pharmacovigilance).

It is planned to enroll approximately 6000 patients (suggested number of patients on WW\~1000 pts, 1L\~2750 pts, RR\~2250 pts)

During the course of study's prospective part, it is planned to carry out at approximately 5 visits:

(if unscheduled visit performed - the information should be filled on nearest visit).

  • Baseline visit: ICF signing, initial patient's data input will be done retrospectively, for patients who are already monitored by investigational site.
  • Interim Visits (CRF will be filled every 6 months for therapy receiving patients and every 12 months for WW patients; if a patient transitions from WW to therapy, his/her CRF will be filled every 6 months; all patient's visits should be planned according routine practice and investigator's judgement on individual basis).
  • Final visit (data collection on 24 months after enrollment): patient's data input will be done for previously enrolled patients (data update)
03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic lymphocytic leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

It is expected to recruit approximately 6000 patients with CLL/SLL regardless of treatment stage and line.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Ability and willing to sign the ICF
  • Diagnosed CLL/SLL (including watch and wait stage of disease) according to Russian clinical guides

Exclusion criteria

Exclusion Criteria:

  • Patients without CLL/SLL diagnosis
  • Age \<18 years
  • Patients who refused/did not sign the ICF
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Sex

    Time frame: Baseline

  2. Date of diagnosis for CLL/SLL

    Time frame: Baseline

  3. Comorbidities

    Time frame: Up to 2 years

  4. ECOG status (0-1/≥2)

    Time frame: Up to 2 years

  5. Rai staging (0-IV)

    Time frame: Up to 2 years

  6. Cytogenetic tests

    * TP53 gene mutation status * IGHV gene mutation status * complex karyotype * del13q status

    Time frame: Up to 2 years

07

Study locations

34 sites
  • Research Site
    Belgorod, Russia
  • Research Site
    Bryansk, Russia
  • Research Site
    Chelyabinsk, Russia
  • Research Site
    Chita, Russia
  • Research Site
    Irkutsk, Russia
  • Research Site
    Kaliningrad, Russia
  • Research Site
    Kaluga, Russia
  • Research Site
    Kazan', Russia
  • Research Site
    Kirov, Russia
  • Research Site
    Krasnoyarsk, Russia
  • Research Site
    Kurgan, Russia
  • Research Site
    Mahachkala, Russia
  • Research Site
    Moscow, Russia
  • Research Site
    Nizhny Novgorod, Russia
  • Research Site
    Novosibirsk, Russia
  • Research Site
    Omsk, Russia
  • Research Site
    Orenburg, Russia
  • Research Site
    Perm, Russia
  • Research Site
    Petropavlovsk-Kamchatskii, Russia
  • Research Site
    Petrozavodsk, Russia
  • Research Site
    Rostov-on-Don, Russia
  • Research Site
    Saint-Petesburg, Russia
  • Research Site
    Samara, Russia
  • Research Site
    Saratov, Russia
  • Research Site
    Syktyvkar, Russia
  • Research Site
    Tver', Russia
  • Research Site
    Ufa, Russia
  • Research Site
    Ulan-Ude, Russia
  • Research Site
    Vladimir, Russia
  • Research Site
    Vladivostok, Russia
  • Research Site
    Volgograd, Russia
  • Research Site
    Vologda, Russia
  • Research Site
    Yaroslavl, Russia
  • Research Site
    Yekaterinburg, Russia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.

Of 34 industry-sponsored observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 66. This study's planned 65 months is above that.

Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 31 and three quarters within 176.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 1, 2021
StartActual
Oct 29, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05140369
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Oct 29, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 3, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion